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Abstract
Recurrent deletions of 2q32q33 have recently been reported as a new microdeletion syndrome. Clinical features of this
syndrome include severe mental retardation, growth retardation, dysmorphic features, thin and sparse hair, feeding
difficulties and cleft or high palate. The commonly deleted region contains at least seven genes. Haploinsufficiency of one of
these genes, SATB2, a DNA-binding protein that regulates gene expression, has been implicated as causative in the cleft or
high palate of individuals with 2q32q33 microdeletion syndrome. In this study we describe three individuals with smaller
microdeletions of this region, within 2q33.1. The deletions ranged in size from 173.1 kb to 185.2 kb and spanned part of
SATB2. Review of clinical records showed similar clinical features among these individuals, including severe developmental
delay and tooth abnormalities. Two of the individuals had behavioral problems. Only one of the subjects presented here
had a cleft palate, suggesting reduced penetrance for this feature. Our results suggest that deletion of SATB2 is responsible
for several of the clinical features associated with 2q32q33 microdeletion syndrome.
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Introduction
Special AT-rich sequence binding protein 2 (SATB2; OMIM
608148) is a DNA-binding protein that regulates gene expression
through chromatin modification and interaction with other
proteins and plays roles in mammalian development [1–4]. In
humans haploinsufficiency has been implicated in isolated cleft
palate (CPI, OMIM 119540) [5,6]. A single case of a de novo
nonsense mutation of SATB2 has been described in an individual
with cleft palate, osteoporosis, profound mental retardation,
epilepsy, a jovial personality, and craniofacial dysmorphism
including gum hyperplasia, mandibular hypoplasia, and anterior-
pointing incisors [7]. Three individuals with apparently balanced
translocations with a breakpoint within SATB2 or in a highly
conserved region 39 of the gene have also been reported [5,8].
Two of these individuals had cleft palate, mild learning disabilities
with speech delay and strikingly similar dysmorphic features with a
prominent nasal bridge, underhanging columella, and a small
mouth with a distinctive upper lip [6]. The third individual was
diagnosed with Toriello-Carey syndrome because of the presence
of Robin sequence, agenesis of the corpus callosum, dysmorphic
features, and global developmental delay [8]. A fourth case of a
balanced translocation predicted to disrupt the SATB2 gene has
been reported in an individual with autism spectrum disorder and
developmental dyspraxia [9]. Mouse studies have shown a role for
Satb2 beyond the palatal shelves, with roles in B-cell differenti-
ation [2], osteoblast differentiation [4], establishment of neural
corticocortical connections across the corpus callosum [3], and in
the developing jaw and incisors [4,10]. Because SATB2 is highly
conserved between species (99.6% between humans and mice), a
deletion of this gene in humans is predicted to affect multiple
systems.
Recently, Van Buggenhout et al. [11] used a 1-Mb bacterial
artificial chromosome (BAC) microarray and characterized
deletions of 2q32.2q33.3 in four individuals with severe mental
retardation and growth retardation, facial dysmorphism, thin and
sparse hair, micrognathia, cleft or high palate, persistent feeding
difficulties, inguinal hernia, and broad-based gait. Three of these
individuals had a distinctive behavioral phenotype with hyperac-
tivity, motor restlessness, chaotic behavior, and happy personality
with periods of aggression and anxiety. The authors suggested
that, based on the common clinical features in these individuals
and several previously reported individuals with cytogenetically
visible deletions of 2q32q33 [12–27], microdeletions of 2q32q33
constitute a distinct syndrome (OMIM 612313). An additional
case of this microdeletion has been reported in a male patient with
a similar phenotype, including severe mental retardation, growth
retardation, dysmorphic features, high palate, hyperactive and
aggressive behavior, and hypotonia in infancy that changed to
hypertonia [28]. Deletion of SATB2 has been suggested to be
responsible for the cleft or high palates in these individuals [11].
We report the clinical and molecular characterization of three
individuals with microdeletions within 2q33.1 spanning part of the
SATB2 gene. From our review of the published literature these
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microdeletion syndrome reported to date and suggest haploinsuf-
ficiency of SATB2 may be responsible for some of the clinical
features associated with the syndrome.
Results
We identified three individuals with microdeletion of 2q33.1
among our patient population. We characterized the deletions in
more detail using a high-density 105K oligonucleotide microarray.
Microarray analysis identified single-copy losses of the region
containing SATB2 in each of the individuals (Figure 1). A 183.6 kb
deletion spanning all but the 59 end of the SATB2 gene at 2q33.1
(chr2:199,837,205–200,020,800) was found in subject 1; a
173.1 kb deletion at 2q33.1 within the SATB2 gene
(chr2:199,860,227–200,033,309) was found in subject 2; and a
185.2 kb deletion at 2q33.1 encompassing all but the 39 end of
SATB2 (chr2:199,860,027–200,045,201) was found in subject 3.
The only gene contained in each of the three deletions was SATB2.
No other clinically significant gains or losses were detected in these
individuals. A search of the Database of Genomic Variants
(projects.tcag.ca/variation/) showed seven normal individuals
have been reported with small deletions in SATB2; however, each
of the deletions was entirely within an intron of the gene.
FISH using BAC probe RP11-404F23 to the SATB2 locus
confirmed a deletion in all subjects. Parental specimens were
available only for the mothers of subjects 1 and 2, and neither
mother carried the deletion of 2q33.1. Biological parents of subject
3 were unavailable for testing.
Clinical information was available for subjects 1–3 (Table 1).
Subject 1 is a 9-year 8-month old female with severe mental
retardation, dysmorphic features, and behavior problems. Family
history was negative for any individuals with similar developmen-
tal delays. The subject was born to a 30-year-old mother via a
somewhat difficult vaginal delivery following a pregnancy
complicated by gestational diabetes. Fetal activity was normal.
Exposures were denied. There was perinatal distress with difficulty
in delivering the head. Labor was induced. Birth weight was 8
pounds 9 ounces. She had a fractured clavicle and some transient
tachypnea and was discharged home at 7 days. Developmental
Figure 1. Analysis of individuals with microdeletions of 2q33.1. (A–D) Oligonucleotide microarray profiles for (A) normal chromosome 2, (B)
a single-copy loss of 183.6 kb at 2q33.1 in subject 1, (C) a single-copy loss 173.1 kb at 2q33.1 in subject 2, and (D) a single-copy loss of 185.2 kb at
2q33.1 in subject 3. For the microarray plots, clones are ordered on the x axis according to physical mapping positions with proximal 2q33.1 to the
left and distal 2q33.1 to the right. (E) Summary of the deletion sizes in individuals with microdeletions encompassing 2q33.1. Green bars indicate the
approximate deletion sizes in individuals in the Van Buggenhout et al. [11] study (upper portion of diagram) and the current study (bottom of
diagram). The SATB2 gene is indicated by a red box.
doi:10.1371/journal.pone.0006568.g001
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placed her IQ below 50. She had delayed primary dentition, with
eruption of her first tooth at age 2. At age 9 years 8 months she has
20 words, four to five signs, and one two-word phrase. Head MRI
at age 2 was normal, and head CT at age 7 was also
unremarkable. She has a heart murmur with no known further
workup. Dysmorphic features include frontal bossing, a long and
narrow face with a prominent maxillary arch, a class II
malocclusion with relative micrognathia, slightly large ears, a
smooth upper lip, and a smooth philtrum (Figure 2A–B). The
subject was uncooperative with direct examination of her palate,
but her history is not consistent with any palatal clefting. At age 9
years 8 months height is at the 25
th–50
th percentile, weight is at the
50
th–75
th percentile, and head circumference is at the 75
th
percentile. She has normal dentition. The subject is very social,
repeats actions multiple times, frequently washes her hands, likes
to have her hair washed, has touch avoidance, has good eye
contact, is somewhat photophobic, and has nodules on the dorsal
surfaces of her fifth fingers bilaterally consistent with the effects of
chewing on her hands.
Subject 2 is a 21-year-old male with severe mental retardation,
dysmorphic features, cleft palate, and behavior problems. The
subject was born to an 18-year-old G3P0R1020 mother at term
via spontaneous vaginal vertex delivery following a pregnancy
complicated by maternal smoking (1/2 pack per day), maternal x-
rays following a car accident, and bleeding at 6 months, followed
by bed rest. Birth weight was at the 50
th percentile. The subject
had a cleft palate, which was repaired before 1 year of age. He had
feeding difficulties as an infant with frequent vomiting. Develop-
mentally, he smiled at 1 month, rolled over at 4 months, and
walked alone at 2–3 years. At age 21 he does not put words
together and is not toilet trained. Formal evaluation at 10 years of













Severe developmental delay/mental retardation 3/3 5/5 15/15
b 1/3
Behavior problems 2/3 4/5 2/9
b 1/3
b,c
Feeding difficulties 1/3 2/5 10/20 1/3
Seizures 0/3 2/5 8/19 1/3
CNS abnormality 0/1 2/3 7/20
d 1/1
Hypotonia 0/3 3/5 5/19 0/3
Hypertonia 1/3 1/5 2/19 0/3
Eye abnormalities 0/3 1/5 8/20 1/3
Growth
IUGR/small size at birth 0/2 2/4 13/16
e 0/2
Postnatal growth retardation 0/3 4/5 15/17
b 1/3
Dysmorphic features
Thin/sparse hair 0/3 5/5 3/19 1/3
Prominent/high forehead 1/3 2/5 4/19 0/3
Dysplastic/low-set ears 0/3 4/5 16/19 1/3
Prominent nasal bridge 1/3 3/5 4/19 2/3
Macroglossia 0/3 1/5 1/19 0/3
Micrognathia 2/3 3/5 14/19 2/3
Craniofacial
Microcephaly 1/3 4/5 14/20 1/3
Macrocephaly 1/3 0/5 0/20 0/3
Cleft palate 1/3 2/5 12/20 3/3
High palate 0/2 3/5 2/19 0/3
Tooth abnormalities 3/3 5/5 4/9
b ?
Cardiovascular
Heart defect 0/3 1/5 5/19 0/3
Genitourinary
Inguinal hernia 0/3 3/5 2/20 0/3
Small genitalia 1/3 3/5 2/19 0/3
aTwenty patients have been reported; one did not have a physical examination [12–27].
bSome cases were not old enough at time of report or death to assess for this feature.
cOne balanced translocation case was reported with autism spectrum disorder and developmental dyspraxia; no other information was given [9].
dOnly one report specifically states lack of CNS abnormality.
eBirth data is not available in all reports.
doi:10.1371/journal.pone.0006568.t001
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include a broad nasal midsection, short tongue, short oropharynx
with poor movement, small mandible with crowded teeth, small
testes, slightly broad thumbs and first toes, prominent heels, and
macrocephaly. Figures 2C and D show subject 2’s facial features at
age 10. At age 21 height is at the 10
th percentile, weight is at the
5
th–10
th percentile, and head circumference is greater than the
98
th percentile (59 cm). Neurological examination revealed
increased tone, normal strength, and deep tendon reflexes
measuring 3+. The subject has a happy demeanor, although he
has a history of aggression at times and will pick his skin. Food is
locked up because of overeating and vomiting, and he will eat non-
food items. He also has a high tolerance for pain.
Subject 2’s family history is significant for a full brother with
speechdelaysasachild,butheisnot havinganyproblemsatage 20.
A paternal half-sister has a cleft lip/palate and mental retardation.
The subject’s father is of normal intellect. There is also a paternal
first cousin who was born with a cleft palate and an unspecified ear
anomaly that required plastic surgery. Two maternal half-sisters are
developmentally normal. Learning disabilities were present in a
maternal uncle and a maternal first cousin. Ancestry is African-
American, and consanguinity was denied.
Subject 3 is a 6-year-old female with severe mental retardation.
She is of Guatemalan ancestry, and no family history information
is available. Developmental delays were noted at 6 months of age.
At 4.5 years, developmental assessment placed her at an 18-month
level. Intelligence testing showed an IQ of 32. On the Vineland
Adaptive Behavior Scale, she had a standard score for adaptive
behavior of 56 with strength in socialization skills and a standard
score of 66 with other scores clustering in the mid 50s. She does
not have any speech, but she does have some signs. The only
dysmorphic features present are borderline microcephaly with
some brachycephaly and fused mandibular central incisors. She
does not have a cleft palate. At age 6 height is at the 75
th
percentile, weight is at the 50
th–75
th percentile, and head
circumference is at the 2
nd percentile (48 cm). The only
troublesome behavior noted by her parents was her inability to
sleep through the night until she was 5 years old.
Discussion
We report the characterization of three individuals with
microdeletions of 2q33.1. The microdeletions range in size from
173.1 kb to 185.3 kb, and each spans part of SATB2. To our
knowledge, these are the smallest deletions associated with the
2q32q33 microdeletion syndrome; the minimal deletion region in
the four individuals reported by Van Buggenhout et al. [11] was
8.1 Mb. The three individuals in the present study had clinical
features characteristic of 2q33.1 microdeletion syndrome, includ-
ing severe developmental delay with little to no speech and tooth
Figure 2. (A) Facial image of subject 1 at age 2 years, 9 months. (B) Facial image of subject 1 at age 9 years, 8 months. Subject is in mixed dentition
and is missing her maxillary central incisors. (C) Front and (D) profile facial images of subject 2 at age 10 years. Note the broad nasal midsection,
small mandible, and macrocephaly.
doi:10.1371/journal.pone.0006568.g002
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behavior.
All three individuals in our study had dentofacial abnormalities.
Subjects 1 and 2 had micrognathia or a small mandible, likely
contributing to the crowding of the teeth. Several of the individuals
previously reported withcytogeneticallyvisibledeletionsof2q32q33
have had dental abnormalities, including missing teeth, abnormally
shaped teeth, malocclusion, and diastema [11,14,22,23,26,28]. The
role of SATB2 in tooth and jaw development is supported by the
identification of a de novo SATB2 mutation in a male with profound
mental retardation and jaw and tooth abnormalities [7] and a
translocation interrupting SATB2 in an individual with Robin
sequence [8]. In addition, mouse models have demonstrated
haploinsufficiency of Satb2 results in craniofacial defects that
phenocopythosecausedby2q32q33 deletioninhumans; moreover,
full functional loss of Satb2 amplifies these defects. Satb2
+/2 mice
have small mouths, premaxillary and nasocapsular hypoplasia,
micrognathia, and variable incisor agenesis. Satb2
2/2 mice have
fully penetrant incisor adontia. Loss of Satb2 correlates with
increased cell death in the developing jaw along with altered
expression of other craniofacial developmental genes [10]. The
individuals reported by Van Buggenhout et al. [11] also presented
withthinandsparsehairand thinandtransparentskin,andtwohad
nail abnormalities. This combination of features is suggestive of an
ectodermal dysplasia, although the individuals in the present study
did not have any of these other ectodermal-related features. The
detection of a deletion of 2q31.2q32.3 that did not encompass
SATB2 in an individual with abnormal teeth and thin skin suggests
other genes in the region mayimpact ectodermaldevelopment [29].
Thus, SATB2 haploinsufficiency likely contributes to the tooth
abnormalities inthe 2q32q33 microdeletion subjects, butdeletion of
other genes may be necessary for the full ectodermal phenotype.
Although haploinsufficiency of SATB2 has been suggested to
cause isolated cleft palate in humans, within our cohort SATB2
deletions show reduced penetrance for cleft palate (Table 1).
Subject 2 is the only individual in this study with a cleft palate, and
his family history was significant for clefting, suggesting there could
be other genetic factors contributing to the clefting. These relatives
were not available for testing to determine their SATB2 genotype.
Incomplete penetrance has been observed in mouse models; one
study of Satb2-haploinsufficient mice showed cleft palate in
approximately 25% [10], whereas another population was
reported as phenotypically normal [4]. Thus, SATB2 haploinsuffi-
ciency alone may not be sufficient for cleft palate; other factors,
environmental or genetic, may need to be present to lead to
clefting.
SATB2 also likely influences brain development, as illustrated by
the severe mental retardation seen in these subjects. This is
consistent with mouse studies that show Satb2 is necessary for
proper establishment of cortical neuron connections across the
corpus callosum [3], despite the apparently normal corpus
callosum in heterozygous knockout mice. One subject in this
report who had brain imaging, subject 1, had a normal study.
A behavioral phenotype in some individuals with 2q32q33
microdeletions further implicates a role of this gene in brain
development. Subjects 1 and 2 in the present study had
characteristic behaviors, including repetitive behaviors, touch
avoidance, chewing on hands, skin picking, aggression, and pica.
Subject 3, who did not have a history of behavior problems, did
have a history of sleeping difficulties. Some of these behaviors
overlap with those seen in previously reported individuals
[11,25,26,28]. Additionally, one individual with a balanced
translocation disrupting SATB2 had autism spectrum disorder
[9]. By excluding the deletion of the individual in their study
without behavioral problems, Van Buggenhout et al. [11]
proposed a 0.5-Mb common deletion region at 2q32.3 proximal
to SATB2 for behavioral problems. However, the presence of a
rather typical behavioral phenotype in two of the individuals in
our report suggests a role for SATB2 haploinsufficiency in these
characteristic behaviors. However, not all individuals with SATB2
abnormalities exhibit behavioral problems; the individuals report-
ed by Brewer et al. [6] with balanced translocations disrupting
SATB2 [5] had mild learning disabilities with speech delay and no
report of behavior problems. Haploinsufficiency for other genes in
the region may also have an impact on behavior, because the
individual with a 2q31.2q32.3 deletion that did not include SATB2
also had hyperactivity, anxiety, aggressiveness, and self mutilation
[29].
Our results suggest haploinsufficiency of SATB2 causes some of
the clinical features associated with the 2q32q33 microdeletion
syndrome, including palate abnormalities, tooth anomalies, MR
and behavior problems. Because many chromosomal syndromes
are caused by more than one gene (contiguous gene syndromes),
identification and characterization of additional individuals may
elucidate the full etiology of this syndrome.
Materials and Methods
Ethics statement
For the individuals with 2q33.1 microdeletions described here,
informed consent was obtained to perform high-resolution
microarray-based molecular cytogenetic testing and to publish
photographs.
Subjects and controls
During the period encompassing November 2007 through
October 2008, we tested 9,773 samples submitted to Signature
Genomic Laboratories from the United States and abroad. The
most common clinical presentations were mental retardation,
developmental delay, or multiple congenital anomalies.
BAC Microarray analysis
Microarray-based comparative genomic hybridization (aCGH)
was performed with a BAC microarray (the SignatureChip;
Signature Genomic Laboratories, Spokane, WA) [30]. The Signa-
tureChip Whole Genome (SignatureChipWG) is currently in use in
this laboratory. Results were visualized using Signature Genomic
Laboratories’ laboratory-developed computer software program
Genoglyphix (http://www.signaturegenomics.com/genoglyphix.
html). Each BAC clone was verified by fluorescence in situ
hybridization (FISH) for its chromosomal location prior to
microarray construction and validated for use in FISH to visualize
chromosomeabnormalitiesidentified bythemicroarray. Microarray
analysis was performed as previously described [31].
Oligonucleotide Microarray analysis
Oligonucleotide-based microarray analysis was performed on
individuals with microdeletions of 2q33.1 using a 105K-feature
whole-genome microarray (SignatureChip Oligo Solution, made
for Signature Genomic Laboratories by Agilent Technologies,
Santa Clara, CA) with one probe every 10 kb in targeted
regions—microdeletion/microduplication syndromes, the pericen-
tromeric regions, subtelomeres and genes in important develop-
mental pathways—and an average probe spacing of one probe
every 35 kb throughout the rest of the genome. Genomic DNA
was extracted from peripheral blood using a Qiagen M48
Biorobot automated DNA extraction system. Purified genomic
DNA was then sonicated and labeled with Alexaflour dyes 555 or
Microdeletions of SATB2
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Carlsbad, CA). Array hybridization and washing was performed as
specified by the manufacturer (Agilent Technologies). Arrays were
scanned using an Axon 4000B scanner (Molecular Devices) and
analyzed using Agilent Feature Extraction software v9.5.1 and
Agilent CGH Analytics software v3.5.14. Results were then
displayed using custom oligonucleotide aCGH analysis software
(Oligoglyphix; Signature Genomic Laboratories).
Genomic sequence analysis
Computational analysis of 2q32q33 was performed using the
annotated May 2006 assembly of the human genome on the
UCSC genome browser (http://genome.ucsc.edu; build hg18).
Fluorescence in situ hybridization
Deletions of the SATB2 locus were confirmed and visualized by
metaphase FISH using BAC clone RP11-404F23 as previously
described [32].
Acknowledgments
We thank Aaron Theisen (Signature Genomic Laboratories, Spokane, WA)
for his critical editing of our manuscript and Sara Minier (Signature
Genomic Laboratories) for assistance with Figure 1.
Author Contributions
Conceived and designed the experiments: LGS. Performed the experi-
ments: BCB. Analyzed the data: JAR BCB BAT LGS. Contributed
reagents/materials/analysis tools: AL EJS CP ASA. Wrote the paper: JAR.
References
1. Britanova O, Akopov S, Lukyanov S, Gruss P, Tarabykin V (2005) Novel
transcription factor Satb2 interacts with matrix attachment region DNA
elements in a tissue-specific manner and demonstrates cell-type-dependent
expression in the developing mouse CNS. Eur J Neurosci 21: 658–668.
2. Dobreva G, Dambacher J, Grosschedl R (2003) SUMO modification of a novel
MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression.
Genes Dev 17: 3048–3061.
3. Alcamo EA, Chirivella L, Dautzenberg M, Dobreva G, Farinas I, et al. (2008)
Satb2 regulates callosal projection neuron identity in the developing cerebral
cortex. Neuron 57: 364–377.
4. Dobreva G, Chahrour M, Dautzenberg M, Chirivella L, Kanzler B, et al. (2006)
SATB2 is a multifunctional determinant of craniofacial patterning and
osteoblast differentiation. Cell 125: 971–986.
5. FitzPatrick DR, Carr IM, McLaren L, Leek JP, Wightman P, et al. (2003)
Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum Mol Genet
12: 2491–2501.
6. Brewer CM, Leek JP, Green AJ, Holloway S, Bonthron DT, et al. (1999) A locus
for isolated cleft palate, located on human chromosome 2q32. Am J Hum Genet
65: 387–396.
7. Leoyklang P, Suphapeetiporn K, Siriwan P, Desudchit T, Chaowanapanja P, et
al. (2007) Heterozygous nonsense mutation SATB2 associated with cleft palate,
osteoporosis, and cognitive defects. Hum Mutat 28: 732–738.
8. Tegay DH, Chan KK, Leung L, Wang C, Burkett S, et al. (2009) Toriello-Carey
syndrome in a patient with a de novo balanced translocation
[46,XY,t(2;14)(q33;q22)] interrupting SATB2. Clin Genet 75: 259–264.
9. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al. (2008) Structural
variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82:
477–488.
10. Britanova O, Depew MJ, Schwark M, Thomas BL, Miletich I, et al. (2006)
Satb2 haploinsufficiency phenocopies 2q32-q33 deletions, whereas loss suggests
a fundamental role in the coordination of jaw development. Am J Hum Genet
79: 668–678.
11. Van Buggenhout G, Van Ravenswaaij-Arts C, Mc Maas N, Thoelen R,
Vogels A, et al. (2005) The del(2)(q32.2q33) deletion syndrome defined by
clinical and molecular characterization of four patients. Eur J Med Genet 48:
276–289.
12. Ramer JC, Mowrey PN, Robins DB, Ligato S, Towfighi J, et al. (1990) Five
children with del (2)(q31q33) and one individual with dup (2)(q31q33) from a
single family: review of brain, cardiac, and limb malformations. Am J Med
Genet 37: 392–400.
13. Ramer JC, Ladda RL, Frankel CA, Beckford A (1989) A review of phenotype-
karyotype correlations in individuals with interstitial deletions of the long arm of
chromosome 2. Am J Med Genet 32: 359–363.
14. Al-Awadi SA, Farag TI, Naguib K, Teebi A, Cuschieri A, et al. (1983) Interstitial
deletion of the long arm of chromosome 2: del(2)(q31q33). J Med Genet 20:
464–465.
15. Benson K, Gordon M, Wassman ER, Tsi C (1986) Interstitial deletion of the
long arm of chromosome 2 in a malformed infant with karyotype
46,XX,del(2)(q31q33). Am J Med Genet 25: 405–411.
16. Buchanan PD, Rhodes RL, Stevenson CE Jr (1983) Interstitial deletion 2q31
leads to q33. Am J Med Genet 15: 121–126.
17. Dallapiccola B, Novelli G, Giannotti A (1988) Deletion 2q31.3–2q33.3: gene
dosage effect of ribulose 5-phosphate 3-epimerase. Hum Genet 79: 92.
18. Franceschini P, Cirillo Silengo M, Davi G, Bianco R, Biagioli M (1983)
Interstitial deletion of the long arm of chromosome 2 (q31q33) in a girl with
multiple anomalies and mental retardation. Hum Genet 64: 98.
19. Glass IA, Swindlehurst CA, Aitken DA, McCrea W, Boyd E (1989) Interstitial
deletion of the long arm of chromosome 2 with normal levels of isocitrate
dehydrogenase. J Med Genet 26: 127–130.
20. Hiroyama Y, Hatanaka H, Ikenoue T, Ishihara Y (1990) Interstitial deletion of
long arm of chromosome 2(q31q33). Acta Paediatr Jpn 32: 563–565.
21. Markovic S, Krstic M, Sulovic V, Radojkovic Z, Adzic S (1985) Interstitial
deletion of chromosome 2. J Med Genet 22: 154–155.
22. Miyazaki K, Yamanaka T, Ogasawara N (1988) Interstitial deletion 2q32.1–q34
in a child with half normal activity of ribulose 5-phosphate 3-epimerase (RPE).
J Med Genet 25: 850–851.
23. Palmer CG, Heerema N, Bull M (1990) Deletions in chromosome 2 and fragile
sites. Am J Med Genet 36: 214–218.
24. Sumi S, Obayashi M, Murakami M, Ito J, Okada N, et al. (1988) Interstitial
deletion of the long arm of chromosome 2: a dose study on isocitrate
dehydrogenase 1. Jinrui Idengaku Zasshi 33: 461–467.
25. Taysi K, Dengler DR, Jones LA, Heersma JR (1981) Interstitial deletion of the
long arm of chromosome 2: case report and review of literature. Ann Genet 24:
245–247.
26. Vogels A, Haegeman J, Fryns JP (1997) Pierre-Robin sequence and severe
mental retardation with chaotic behaviour associated with a small interstitial
deletion in the long arm of chromosome 2 (del(2)(q331q333)). Genet Couns 8:
249–252.
27. Young RS, Shapiro SD, Hansen KL, Hine LK, Rainosek DE, et al. (1983)
Deletion 2q: two new cases with karyotypes 46,XY,del(2)(q31q33) and
46,XX,del(2)(q36). J Med Genet 20: 199–202.
28. de Ravel TJ, Balikova I, Thiry P, Vermeesch JR, Frijns JP (2009) Another
patient with a de novo deletion further delineates the 2q33.1 microdeletion
syndrome. Eur J Med Genet.
29. Mencarelli MA, Caselli R, Pescucci C, Hayek G, Zappella M, et al. (2007)
Clinical and molecular characterization of a patient with a 2q31.2-32.3 deletion
identified by array-CGH. Am J Med Genet A 143A: 858–865.
30. Bejjani BA, Saleki R, Ballif BC, Rorem EA, Sundin K, et al. (2005) Use of
targeted array-based CGH for the clinical diagnosis of chromosomal imbalance:
Is less more? Am J Med Genet A 134: 259–267.
31. Ballif BC, Theisen A, Coppinger J, Gowans GC, Hersh JH, et al. (2008)
Expanding the clinical phenotype of the 3q29 microdeletion syndrome and
characterization of the reciprocal microduplication. Mol Cytogenet 1: 8.
32. Shaffer LG, McCaskill C, Han JY, Choo KH, Cutillo DM, et al. (1994)
Molecular characterization of de novo secondary trisomy 13. Am J Hum Genet
55: 968–974.
Microdeletions of SATB2
PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6568